

Diana RuÃ- z Genao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7704670/publications.pdf>

Version: 2024-02-01

15
papers

198
citations

1163117

8
h-index

1058476

14
g-index

17
all docs

17
docs citations

17
times ranked

187
citing authors

#	ARTICLE	IF	CITATIONS
1	A case of IgA pemphigus successfully treated with acitretin. <i>British Journal of Dermatology</i> , 2002, 147, 1040-1042.	1.5	31
2	Pityriasis Rubra Pilaris Successfully Treated with Infliximab. <i>Acta Dermato-Venereologica</i> , 2007, 87, 552-553.	1.3	26
3	Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2821-2829.	2.4	24
4	Fixed drug eruption due to loratadine. <i>British Journal of Dermatology</i> , 2002, 146, 524-540.	1.5	21
5	Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis. <i>British Journal of Dermatology</i> , 2004, 150, 132-135.	1.5	16
6	Pustular acral erythema in a patient with acute graft-versus-host disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003, 17, 550-553.	2.4	15
7	Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort. <i>British Journal of Dermatology</i> , 2017, 176, 797-799.	1.5	13
8	Livedo reticularis associated with interferon alpha therapy in two melanoma patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 252-254.	2.4	8
9	Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años. Datos obtenidos del registro español Biobadaderm. <i>Actas Dermo-sifiliográficas</i> , 2020, 111, 752-760.	0.4	6
10	Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e65-e67.	2.4	6
11	Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry. <i>British Journal of Dermatology</i> , 2022, 187, 817-820.	1.5	6
12	Acute severe form of lichenoid graft-versus-host disease after donor lymphocyte infusions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 632-634.	2.4	4
13	Delphi-based recommendations for the management of cardiovascular comorbidities in patients with psoriatic arthritis and moderate-to-severe psoriasis. <i>Rheumatology International</i> , 2020, 40, 969-981.	3.0	4
14	Manejo de los tratamientos biológicos en pacientes con psoriasis moderada-grave sometidos a intervenciones quirúrgicas en el registro español Biobadaderm. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 52-58.	0.4	3
15	Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) breastfeed less when compared with general population. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	2